MicuRx Pharmaceutical’s anti-infection drug MRX-5 has been granted Orphan Drug Designation (ODD) by the US Food and Drug Administration (FDA) for the treatment of non-tuberculous mycobacteria (NTM) infections. MRX-5 is a novel benzoxazole antibiotic developed for the treatment of mycobacteria infections, particularly infections caused by non-tuberculous Mycobacteria (NTM). In recent years, NTM diseases have been […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!